SELLAS Life Sciences Group, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
SELLAS Life Sciences Group, Inc. (SLS) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-19
- SELLAS Life Sciences Group, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $2.00M, a 4.76% decline from fiscal 2024.
- SELLAS Life Sciences Group, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $2.10M, a 16.00% decline from fiscal 2023.
- SELLAS Life Sciences Group, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $2.50M, a 30.56% decline from fiscal 2022.
- SELLAS Life Sciences Group, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $3.60M, a 200.00% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.00M 10-K · filed 2026-03-19 | |
| 2024-12-31 | $2.10M 10-K · filed 2025-03-20 | |
| 2023-12-31 | $2.50M 10-K · filed 2024-03-28 | |
| 2022-12-31 | $3.60M 10-K · filed 2023-03-16 | |
| 2021-12-31 | $1.20M 10-K · filed 2022-03-31 | |
| 2020-12-31 | -$1.50M 10-K · filed 2021-03-23 | |
| 2019-12-31 | $1.60M 10-K · filed 2020-03-13 | |
| 2018-12-31 | $1.40M 10-K · filed 2019-03-22 | |
| 2017-12-31 | $1.20M 10-K · filed 2018-04-13 | |
| 2016-12-31 | $1.80M 10-K · filed 2018-04-13 | $21.80M 10-K · filed 2017-03-15 |
| 2015-12-31 | $24.20M 10-K · filed 2017-03-15 | $24.00M 10-K · filed 2016-03-10 |
| 2014-12-31 | $17.40M 10-K/A · filed 2016-04-15 | $17.20M 10-K · filed 2015-03-05 |
| 2013-12-31 | $12.50M 8-K · filed 2015-12-04 | |
| 2012-12-31 | $5.10M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |